ArticleEuropean radiology experimental2026
Photon-counting CT-guided bone biopsy with real-time bone marrow edema mapping.
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Understanding Photon-Counting CT: Physics, Detector Technology, and Image Reconstructions.Sensors (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveComputed tomography-guided biopsies are needed to diagnose bone lesions, but can sometimes be challenging. We evaluated the feasibility and usefulness of photon-counting computed tomography (PCCT)-guided bone biopsies, focusing on real-time bone marrow oedema (BME) mapping to optimise diagnostic yield. MATERIALS AND
methodsThis retrospective single-centre study included procedures performed from September 2024 to May 2025 using a first-generation dual-source PCCT scanner with Quantum HD mode. Ten consecutive patients underwent PCCT-guided bone biopsy with real-time BME reconstructions. The reference standard was established using histopathology or microbiological confirmation when available; clinical and ≥ 3-month radiologic follow-up for nondiagnostic or discordant results. Statistical analysis included descriptive statistics, independent unpaired t-tests, and correlation analysis (SPSS v22.0, RStudio).
resultsTen patients, five women and five men, aged 60.5 ± 13.5 years (mean ± standard deviation), were included in the final analysis. The overall diagnostic yield was 70% (7/10), with a diagnostic accuracy of 87.5% (7/8) for cases with a definitive reference standard. Final diagnoses comprised tumour bone metastases (n = 7, 70%), bone osteomyelitis (n = 1, 10%), and bone marrow deposition disease (n = 2, 20%). Mean radiation dose (dose-length product) was 644.5 ± 112.1 mGy·cm. Monoenergetic 70-keV imaging showed significant differences between mean HU values of lytic (42.6) and sclerotic lesions (476.2) (p = 0.009), with a strong negative correlation between lesion morphology (sclerotic versus lytic) and monoenergetic 70-keV attenuation values (r = -0.84; p = 0.002).
conclusionPCCT-guided bone biopsy with real-time BME mapping proved feasible and showed encouraging diagnostic performance in this small exploratory cohort. Larger validation studies are needed. RELEVANCE STATEMENT: By combining monoenergetic images and BME mapping, PCCT-guided bone biopsy improves lesion visualisation, operator confidence, procedural efficiency, and overall safety for diagnostic tissue sampling and active disease targeting. KEY POINTS: Accurate targeting of active disease within complex bone lesions during CT-guided biopsy remains challenging sometimes. PCCT-guided biopsy with real-time BME mapping can enhance lesion targeting and procedural efficiency. PCCT-guided biopsy may improve safety, diagnostic accuracy, and operator confidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.